Uday Bhatt1, Chandrashekar Balachandran2, Paul McCartney3, Aldo Martinez4, Ruth Lapid-Gortzak5
Purpose: To clinically evaluate the performance of the AcrySof IQ PanOptix and AT LISA tri 839MP IOLs for binocular vision at distance, intermediate and near photopic conditions and to characterize the low contrast performance with both IOLs.
Method: A prospective, multi-centre (15 sites), post market, parallel group, double-masked, randomized clinical trial involving bilateral implantation of PanOptix or AT LISA tri 839MP Presbyopia Correct- ing IOL in 182 subjects. Binocular Uncorrected Dis- tance VA (4 m), Binocular Uncorrected intermediate VA (60cm), Binocular Uncorrected near VA (40cm) and Binocular defocus curves were evaluated under photopic lighting conditions. Photopic and Mesopic contrast sensitivities with and without glare were also evaluated.
Results: A total of 180 subjects (39% M: 61% F) with a mean age of 66 9.4 years completed the trial after bilateral implantation of PanOptix IOL (n = 93) or with the AT LISA tri 839MP IOL (n =
87) and followed up for 6 months (120-180 days). At 6-months, the PanOptix group showed superior visual outcomes in UCIVA (P < 0.002), UCNVA (P < 0.003) and non-inferior UCDVA (95% SCI < 0.1 log- MAR). The mean Defocus curve from 0.00D to -3.00D ranged from 0.1 to 0.0 logMAR in both lenses but higher mean VA was observed in the PanOptix group between −1.50D to −2.50D. Con- trast Sensitivity values were similar between the two groups in all conditions. Conclusion: The results of this study conﬁrm bench and in-vitro predictions of superior visual perfor- mance at near and intermediate distances with the AcrySof IQ PanOptix IOL compared to AT LISA tri 839MP IOL.